Anteris Technologies Global Corp. (ATGC) has announced its financial results for the quarter ended June 30, 2025. The company reported a decrease in revenues from ordinary activities, amounting to $1.174 million, compared to $1.398 million in the same period last year, reflecting a decline of 16%. The loss from ordinary activities after tax increased by 23%, totaling $42.993 million compared to $34.972 million in the previous year. The loss for the period attributable to members was $42.698 million, up 22% from $35.057 million in 2024. No dividend has been proposed or declared for the reporting period. Significant business activities during the quarter included ongoing development of DurAVR® THV and preparation for its Pivotal Trial in treating severe aortic stenosis. The company utilized $37.6 million of proceeds from its initial public offering for this development, and an additional $14.1 million for net working capital and other general corporate purposes. Payments totaling $640,000 were made to related parties and their associates, covering various remunerations and fees within the company's operating activities.